Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-034427
Filing Date
2025-11-12
Accepted
2025-11-12 16:02:52
Documents
62
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q sava20250930_10q.htm   iXBRL 10-Q 1081556
2 EXHIBIT 31.1 ex_855814.htm EX-31.1 13769
3 EXHIBIT 31.2 ex_855815.htm EX-31.2 13872
4 EXHIBIT 32.1 ex_855816.htm EX-32.1 7598
  Complete submission text file 0001437749-25-034427.txt   5456442

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA sava-20250930.xsd EX-101.SCH 49617
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE sava-20250930_cal.xml EX-101.CAL 30957
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20250930_def.xml EX-101.DEF 315798
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20250930_lab.xml EX-101.LAB 288028
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20250930_pre.xml EX-101.PRE 344854
65 EXTRACTED XBRL INSTANCE DOCUMENT sava20250930_10q_htm.xml XML 886842
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41905 | Film No.: 251472492
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)